<DOC>
	<DOCNO>NCT01356173</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I , dose-escalation study ass safety , tolerability , pharmacokinetic ( PK ) GDC-0349 administer daily ( QD ) , orally ( PO ) .</brief_summary>
	<brief_title>Evaluating Safety Tolerability GDC-0349 Patients With Locally Advanced Metastatic Solid Tumors Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically document , locally advanced metastatic solid malignancy NHL without leukemic phase progress failed respond least one prior regimen and/or candidate regimen know provide clinical benefit Evaluable measurable disease per RECIST v1.1 IWG response criterion patient NHL and/or follow : prostate cancer patient nonmeasurable disease eligible two rise prostatespecific antigen ( PSA ) level &gt; = 5 ng/mL measure &gt; = 2 week apart meet PSA , Working Group criteria progression prior initiation study treatment , ovarian cancer patient nonmeasurable disease eligible two rise CA125 level great ULN &gt; = 2 week apart prior initiation study treatment . ECOG performance status 0 1 screen Life expectancy &gt; = 12 week Adequate hematologic organ function within 14 day prior initiation study treatment Documented willingness use effective mean contraception men woman participate study 90 day last dose GDC0349 Willingness provide archival tumor tissue Leptomeningeal disease manifestation current malignancy History Type 1 2 diabetes require daily medication Known untreated central nervous system ( CNS ) malignancy treat brain metastasis radiographically stable &gt; = 3 month prior initiation study treatment Active congestive heart failure ventricular arrhythmia require medication Uncontrolled ascites require weekly largevolume paracentesis 3 consecutive week prior initiation study treatment Active infection require intravenous ( IV ) antibiotic Patients require daily supplemental oxygen Uncontrolled hypomagnesemia hypokalemia Any condition require anticoagulant warfarin , heparin , antithrombotics . Prophylactic anticoagulation and/or local application thrombolytic agent catheter patency may allow patient normal INR prior approval Medical Monitor Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus ( HIV ) infection Any disease , active uncontrolled pulmonary dysfunction , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , may affect interpretation result , render patient high risk treatment complication Significant traumatic injury within 3 week prior initiation GDC0349 Major surgical procedure within 4 week prior initiation GDC0349 Treatment chemotherapy , hormonal therapy ( except GnRH agonists antagonist prostate cancer ) , immunotherapy , biologic therapy , radiation therapy ( except palliative radiation bony metastasis ) cancer therapy within 4 week prior initiation study treatment . Kinase inhibitor , approve national regulatory authority , may use 2 week prior initiation GDC0349 , provide drugrelated toxicity completely resolve prior approval obtain Medical Monitor . Palliative radiation bony metastasis within 2 week prior initiation GDC0349 Treatment investigational agent within 4 week prior initiation GDC0349 Unresolved toxicity prior therapy , except alopecia Grade 1 peripheral neuropathy Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>solid cancer</keyword>
</DOC>